-+ 0.00%
-+ 0.00%
-+ 0.00%

UroGen Pharma Highlights Presentation Of uTRACT Registry Study Design At 2025 ASCO Annual Meeting

Benzinga·06/02/2025 15:01:52
Listen to the news

UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights the presentation of the uTRACT Registry study design at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. The uTRACT Registry is a single-arm, multicenter, prospective and retrospective study evaluating the real-world use of JELMYTO® (mitomycin) for pyelocalyceal solution for the treatment of adult patients with low-grade upper tract urothelial carcinoma (LG-UTUC) across the United States.